Wunderman Thompson Partners with Tealium
Tealium, the trusted leader in real-time customer data orchestration, today announces a partnership with Wunderman Thompson, a WPP company, to integrate Tealium’s AudienceStream CDP as the Profile Streaming Engine for its Customer Cloud.
Wunderman Thompson’s Customer Cloud brings brands and people together for relevant and timely conversations, acting as the hub and clearinghouse for customer data. This platform integrates a brand’s Adtech, Martech, and other data ecosystems to create, manage, enhance, enrich, update, syndicate and activate a comprehensive profile of their customers. This innovation powers relevant and personalised experiences whenever and wherever those experiences occur, driving deeper engagement, action and higher conversions. Tealium AudienceStream CDP serves as the neutral layer of the profiles within the technology stack, syndicating and updating an enriched single view of the customer across all touchpoints, allowing experiences to be informed with the latest and best information.
“We’re excited to partner with Tealium because the technology allows us to update and syndicate consumer profiles in real time across the Adtech ecosystems, empowering our clients to deploy powerful experiences for their customers,” said Jacques van Niekerk, CEO of Wunderman Thompson Data. “With Tealium, our Customer Cloud is able to connect to the browser, ingest signals, identify the customer, update their profile, and act on this information with just the right content for the micro-moment, all within milliseconds.”
“Wunderman Thompson is on the cutting edge of data-driven engagement, so we are proud to serve as the customer data orchestration layer enabling relevant, personalised experiences for their clients,” said Mike Anderson, Founder and CTO of Tealium. “We look forward to seeing the impact our integration makes with Wunderman Thompson’s Customer Cloud and how that ultimately helps Wunderman Thompson clients deliver incredible customer experiences.”
In addition to Tealium’s AudienceStream CDP, Tealium offers a complete portfolio of solutions within Tealium’s Universal Data Hub, which includes Tealium iQ Tag Management, EventStream (API Hub) and DataAccess. Tealium also offers a Consent Management solution for addressing GDPR and CCPA requirements and pre-built connectors to hundreds of digital data sources.
To learn more about Tealium’s solutions, visit www.tealium.com.
About Tealium
Tealium revolutionises today’s digital businesses with a universal approach to customer data orchestration – spanning web, mobile, offline and Internet of Things devices. With the power to unify customer data into a single source of truth, Tealium offers a turnkey integration ecosystem supporting more than 1,200 client-side and server-side vendors and technologies. The Tealium Universal Data Hub encompasses tag management, API hub, customer data platform, and data management solutions that enable organisations to leverage real-time data to create richer, more personalised digital experiences across every team, technology, and customer touchpoint.
For more information, visit www.tealium.com.
About Wunderman Thompson
Wunderman Thompson is a creative, data and technology agency built to inspire growth for its clients and people. Our experts deliver end-to-end solutions at a global scale with an entrepreneurial spirit that infuses creativity with emerging technology to deliver revolutionary work. Headquartered in New York, we are a worldwide agency bringing together over 20,000 people in 90 markets across the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005725/en/
Contact information
Beki Hayler
Account Manager, GingerMay
beki.hayler@teamgingermay.com
T: +44 (0)203 642 1124
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom